研究表明，抑制lipin1表达不仅改变神经元内脂类代谢，而且通过PA和LPA来激活mTOR和STAT3信号通路，从而决定CNS轴突再生能力。 2019年，香港科技大学刘 ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

A recent study in the field of neurobiology, presented in Science China Life Sciences, uncovers a pivotal role for the ...

A collaborative study in neuroscience, spearheaded by a research team of the Hong Kong University of Science and Technology ...

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive ...

Dr. Iweka discovered that PLPPR1 impedes the inhibitory activity of CSPGs and other inhibitory molecules such as lysophosphatidic acid, by modulating Rho-GTPases during CNS injury. During her ...

Biochem J. 2007 Oct 15;407(2):243-54. PubMed PMID: 17617061. Khurana S, Tomar A, George SP, Wang Y, Siddiqui MR, Guo H, Tigyi G, Mathew S. Autotaxin and lysophosphatidic acid stimulate intestinal cell ...

Robert W. Baird started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research note issued to ...